236 related articles for article (PubMed ID: 32327714)
1. The deubiquitylase USP2 maintains ErbB2 abundance via counteracting endocytic degradation and represents a therapeutic target in ErbB2-positive breast cancer.
Zhang J; Liu S; Li Q; Shi Y; Wu Y; Liu F; Wang S; Zaky MY; Yousuf W; Sun Q; Guo D; Wang T; Zhang Y; Wang Y; Li M; Liu H
Cell Death Differ; 2020 Sep; 27(9):2710-2725. PubMed ID: 32327714
[TBL] [Abstract][Full Text] [Related]
2. Identification of an HSP90 modulated multi-step process for ERBB2 degradation in breast cancer cells.
Castagnola P; Bellese G; Birocchi F; Gagliani MC; Tacchetti C; Cortese K
Oncotarget; 2016 Dec; 7(51):85411-85429. PubMed ID: 27863425
[TBL] [Abstract][Full Text] [Related]
3. Neratinib induces ErbB2 ubiquitylation and endocytic degradation via HSP90 dissociation in breast cancer cells.
Zhang Y; Zhang J; Liu C; Du S; Feng L; Luan X; Zhang Y; Shi Y; Wang T; Wu Y; Cheng W; Meng S; Li M; Liu H
Cancer Lett; 2016 Nov; 382(2):176-185. PubMed ID: 27597738
[TBL] [Abstract][Full Text] [Related]
4. Protein kinase C mediated internalization of ErbB2 is independent of clathrin, ubiquitination and Hsp90 dissociation.
Dietrich M; Malik MS; Nikolaysen F; Skeie M; Stang E
Exp Cell Res; 2018 Oct; 371(1):139-150. PubMed ID: 30098331
[TBL] [Abstract][Full Text] [Related]
5. Marked enhancement of lysosomal targeting and efficacy of ErbB2-targeted drug delivery by HSP90 inhibition.
Raja SM; Desale SS; Mohapatra B; Luan H; Soni K; Zhang J; Storck MA; Feng D; Bielecki TA; Band V; Cohen SM; Bronich TK; Band H
Oncotarget; 2016 Mar; 7(9):10522-35. PubMed ID: 26859680
[TBL] [Abstract][Full Text] [Related]
6. The HSP90 inhibitor geldanamycin perturbs endosomal structure and drives recycling ErbB2 and transferrin to modified MVBs/lysosomal compartments.
Cortese K; Howes MT; Lundmark R; Tagliatti E; Bagnato P; Petrelli A; Bono M; McMahon HT; Parton RG; Tacchetti C
Mol Biol Cell; 2013 Jan; 24(2):129-44. PubMed ID: 23154999
[TBL] [Abstract][Full Text] [Related]
7. Flotillin depletion affects ErbB protein levels in different human breast cancer cells.
Asp N; Pust S; Sandvig K
Biochim Biophys Acta; 2014 Sep; 1843(9):1987-96. PubMed ID: 24747692
[TBL] [Abstract][Full Text] [Related]
8. A combination of Trastuzumab and 17-AAG induces enhanced ubiquitinylation and lysosomal pathway-dependent ErbB2 degradation and cytotoxicity in ErbB2-overexpressing breast cancer cells.
Raja SM; Clubb RJ; Bhattacharyya M; Dimri M; Cheng H; Pan W; Ortega-Cava C; Lakku-Reddi A; Naramura M; Band V; Band H
Cancer Biol Ther; 2008 Oct; 7(10):1630-40. PubMed ID: 18769124
[TBL] [Abstract][Full Text] [Related]
9. A kinase inhibitor screen reveals protein kinase C-dependent endocytic recycling of ErbB2 in breast cancer cells.
Bailey TA; Luan H; Tom E; Bielecki TA; Mohapatra B; Ahmad G; George M; Kelly DL; Natarajan A; Raja SM; Band V; Band H
J Biol Chem; 2014 Oct; 289(44):30443-30458. PubMed ID: 25225290
[TBL] [Abstract][Full Text] [Related]
10. Polypeptide-based nanogels co-encapsulating a synergistic combination of doxorubicin with 17-AAG show potent anti-tumor activity in ErbB2-driven breast cancer models.
Desale SS; Raja SM; Kim JO; Mohapatra B; Soni KS; Luan H; Williams SH; Bielecki TA; Feng D; Storck M; Band V; Cohen SM; Band H; Bronich TK
J Control Release; 2015 Jun; 208():59-66. PubMed ID: 25660204
[TBL] [Abstract][Full Text] [Related]
11. Clathrin-independent endocytosis of ErbB2 in geldanamycin-treated human breast cancer cells.
Barr DJ; Ostermeyer-Fay AG; Matundan RA; Brown DA
J Cell Sci; 2008 Oct; 121(Pt 19):3155-66. PubMed ID: 18765569
[TBL] [Abstract][Full Text] [Related]
12. ErbB2 trafficking and degradation associated with K48 and K63 polyubiquitination.
Marx C; Held JM; Gibson BW; Benz CC
Cancer Res; 2010 May; 70(9):3709-17. PubMed ID: 20406983
[TBL] [Abstract][Full Text] [Related]
13. Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin.
Austin CD; De Mazière AM; Pisacane PI; van Dijk SM; Eigenbrot C; Sliwkowski MX; Klumperman J; Scheller RH
Mol Biol Cell; 2004 Dec; 15(12):5268-82. PubMed ID: 15385631
[TBL] [Abstract][Full Text] [Related]
14. Preclinical antitumor activity of the novel heat shock protein 90 inhibitor CH5164840 against human epidermal growth factor receptor 2 (HER2)-overexpressing cancers.
Ono N; Yamazaki T; Nakanishi Y; Fujii T; Sakata K; Tachibana Y; Suda A; Hada K; Miura T; Sato S; Saitoh R; Nakano K; Tsukuda T; Mio T; Ishii N; Kondoh O; Aoki Y
Cancer Sci; 2012 Feb; 103(2):342-9. PubMed ID: 22050138
[TBL] [Abstract][Full Text] [Related]
15. Cholesterol content in cell membrane maintains surface levels of ErbB2 and confers a therapeutic vulnerability in ErbB2-positive breast cancer.
Zhang J; Li Q; Wu Y; Wang D; Xu L; Zhang Y; Wang S; Wang T; Liu F; Zaky MY; Hou S; Liu S; Zou K; Lei H; Zou L; Zhang Y; Liu H
Cell Commun Signal; 2019 Feb; 17(1):15. PubMed ID: 30786890
[TBL] [Abstract][Full Text] [Related]
16. Inhibiting the HSP90 chaperone destabilizes macrophage migration inhibitory factor and thereby inhibits breast tumor progression.
Schulz R; Marchenko ND; Holembowski L; Fingerle-Rowson G; Pesic M; Zender L; Dobbelstein M; Moll UM
J Exp Med; 2012 Feb; 209(2):275-89. PubMed ID: 22271573
[TBL] [Abstract][Full Text] [Related]
17. Endocytic down-regulation of ErbB2 is stimulated by cleavage of its C-terminus.
Lerdrup M; Bruun S; Grandal MV; Roepstorff K; Kristensen MM; Hommelgaard AM; van Deurs B
Mol Biol Cell; 2007 Sep; 18(9):3656-66. PubMed ID: 17626164
[TBL] [Abstract][Full Text] [Related]
18. Ubiquitination and downregulation of ErbB2 and estrogen receptor-alpha by kinase inhibitor MP-412 in human breast cancer cells.
Suzuki T; Fujii A; Ochi H; Nakamura H
J Cell Biochem; 2011 Sep; 112(9):2279-86. PubMed ID: 21503962
[TBL] [Abstract][Full Text] [Related]
19. ErbB2 degradation mediated by the co-chaperone protein CHIP.
Zhou P; Fernandes N; Dodge IL; Reddi AL; Rao N; Safran H; DiPetrillo TA; Wazer DE; Band V; Band H
J Biol Chem; 2003 Apr; 278(16):13829-37. PubMed ID: 12574167
[TBL] [Abstract][Full Text] [Related]
20. Antitumor efficacy of IPI-504, a selective heat shock protein 90 inhibitor against human epidermal growth factor receptor 2-positive human xenograft models as a single agent and in combination with trastuzumab or lapatinib.
Leow CC; Chesebrough J; Coffman KT; Fazenbaker CA; Gooya J; Weng D; Coats S; Jackson D; Jallal B; Chang Y
Mol Cancer Ther; 2009 Aug; 8(8):2131-41. PubMed ID: 19671750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]